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Catherine D. Hughes* , David L. Scott, Fowzia Ibrahim and on behalf of TITRATE Programme Investigators
Abstract
Background: We systematically reviewed the effectiveness of intensive treatment strategies in achieving remission
in patients with both early and established Rheumatoid Arthritis (RA).
Methods: A systematic literature review and meta-analysis evaluated trials and comparative studies reporting
remission in RA patients treated intensively with disease modifying anti-rheumatic drugs (DMARDs), biologics and
Janus Kinase (JAK) inhibitors. Analysis used RevMan 5.3 to report relative risks (RR) in random effects models with
95% confidence intervals (CI).
Results: We identified 928 publications: 53 studies were included (48 superiority studies; 6 head-to-head trials). In the
superiority studies 3013/11259 patients achieved remission with intensive treatment compared with 1211/8493 of
controls. Analysis of the 53 comparisons showed a significant benefit for intensive treatment (RR 2.23; 95% CI 1.90,
2.61). Intensive treatment increased remissions in both early RA (23 comparisons; RR 1.56; 1.38, 1.76) and established RA
(29 comparisons RR 4.21, 2.92, 6.07). All intensive strategies (combination DMARDs, biologics, JAK inhibitors) increased
remissions. In the 6 head-to-head trials 317/787 patients achieved remission with biologics compared with 229/671 of
patients receiving combination DMARD therapies and there was no difference between treatment strategies (RR 1.06;
0.93. 1.21). There were differences in the frequency of remissions between early and established RA. In early RA the
frequency of remissions with active treatment was 49% compared with 34% in controls. In established RA the
frequency of remissions with active treatment was 19% compared with 6% in controls.
Conclusions: Intensive treatment with combination DMARDs, biologics or JAK inhibitors increases the frequency of
remission compared to control non-intensive strategies. The benefits are seen in both early and established RA.
Keywords: Outcome, Early or established rheumatoid arthritis, Treatment response, Remission
Background
Remission has become a key treatment goal in rheumatoid
arthritis (RA). Achieving remission with drug treatment is
recommended in many clinical management guidelines
[1–6]. It is also a central feature of the “treat-to-target”
initiative [7, 8]. Patients who achieve remission have less
disability and better quality of life than those with persist-
ing inflammatory disease [9]. In early RA remission is par-
ticularly important due to the ‘window of opportunity’
during which early intensive treatment can halt or
substantially reduce subsequent disease progression [10].
There are several definitions of remission in RA. The
2010 European League Against Rheumatism (EULAR)
and American College of Rheumatology (ACR) criteria
provided a framework for considering these different defi-
nitions [11]. A variety of composite measures are used to
determine the presence of remission. These include the
Disease Activity Score (DAS) and the Disease Activity
Score for 28 joints (DAS28), the Simple Disease Activity
Score (SDAI) and the Clinical Disease Activity Score
(CDAI) [12–14]. DAS28 remission criteria have been used
most frequently in trials of intensive treatments in RA,
though there has been debate whether it is ideal [15].
Several systematic reviews have reported on treatment
remissions in RA [16–20], patients likely to achieve remis-
sion [21, 22] and the strength of the rationale for treat-
ment to target approaches in RA [23, 24]. The balance of
evidence from these reviews is that intensive treatment
increases remission. However, several uncertainties need
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to be resolved. Firstly, the relative merits of intensive treat-
ment in early RA compared to established disease need to
be considered. Secondly, it is important to know whether
treatment with one type of therapy, such as biologics like
tumour necrosis factor (TNF) inhibitors, will lead to more
remissions than treatment with combinations of conven-
tional disease modifying anti-rheumatic drugs (DMARDs)
Finally it is important to know if one or other treatment
strategy is preferable in early or established disease.
We have systematically reviewed RA clinical trials that
report remissions. We evaluated both trials that compare
an intensive treatment strategy with standard care and
also head-to-head trials of different intensive treatment
strategies. We analysed trials in early and established RA
separately, taking the division between these groups as
usually being 12 months since diagnosis.
Methods
Inclusion and exclusion criteria
The inclusion criteria were: randomized controlled trials or
open label non-randomised comparative studies with at
least one intensive treatment arm and one control arm;
adult patients with RA; studies of at least 6 months dur-
ation; studies enrolling at least 50 patients; studies report-
ing remissions; studies using treatments in their licensed
indication for RA. The intensive treatment arms used
drugs considered more intensive than DMARD monother-
apy. These included combination DMARDs (which could
involve using short-term regular doses of steroids to
control synovitis), TNF inhibitors, non-TNF biologics
(tocilizumab, abatacept and rituximab), and Janus Kinase
(JAK) inhibitors. We also noted whether studies used a
treat-to-target approach with intensive treatments. Studies
either compared one intensive treatment strategy against
standard care or two different intensive treatment strat-
egies (such as combination DMARDs and TNF inhibitors
with DMARDs). Foreign language papers and published
conference abstracts were excluded. Trials comparing simi-
lar types of treatment, such as two intensive DMARD
regimens, were also excluded. The search identified publi-
cations from 1st January 2000 to 30th April 2017.
Search strategy
A systematic literature search was carried out using
EMBASE, OVID Medline as well as hand searching the
systematic reviews relevant to this topic found in the
Cochrane library database. The key word search terms
used were ‘arthritis, rheumatoid’ (MeSH), ‘clinical trial’
[Publication Type] (MeSH), randomised controlled trial
[Publication Type] (MeSH), open label (free text) and
‘remission’ (free text). These were searched separately and
in combination. The EMBASE search terms included
‘arthritis, rheumatoid’ (MeSH) all subheadings and
FOCUS function, clinical trial (MeSH) Explode function.
Data collection
Two researchers (CH, DLS) independently assessed studies
for eligibility and extracted data. This included year of
publication, disease duration, number of treatment groups,
study design, control and intensive treatment regimens,
study size, remissions and study end-points. The numbers
of patients achieving disease remission at the trial
end-point was defined by Disease Activity Scores (DAS) <
1.6, DAS28 < 2.6 or equivalent criteria. The trials were
classified as early (generally with disease durations < 1 year)
or established (generally with disease durations > 1 year)
reflecting the trial investigators assessments. When there
were differences between assessors, they reviewed the
reports together and came to a joint conclusion.
Assessing Bias
A quality assessment was completed for each paper
using the Cochrane Collaboration tool for assessing risk
of bias [25]. The types of bias assessed were: random
sequence generation, selection bias, performance bias,
detection bias, attrition bias, reporting bias and other
bias (such as pharmaceutical funding). The risk was
defined as low or high. We also used funnel plots to
assess publication bias and associated issues [26].
Statistical analysis
Results were analysed using Review Manager 5.3 (Cochrane
Collaboration, Oxford, UK). The random effects model
based on DerSimonian and Laird’s method [27] was used
to estimate the pooled effect sizes; this gives more equal
weighting to studies of different precision in comparison
with a simple inverse variance weighted approach, so
accommodating between study heterogeneity. For all meta-
analyses, we performed Cochrane’s chi-squared test to
assess between study heterogeneity and quantified I2 statis-
tics [25]. P-values < 0.05 were considered significant.
Some of the randomised controlled trials had more
than two treatment arms: when there were two control
groups the results were combined; when there were two
or more intensive treatment groups only those reporting
licensed dosage regimens were included.
Results
Study selection
We identified 928 publications: 440 were duplicated
studies and 414 were excluded after reviewing abstracts.
Seventy four full text papers were reviewed in detail; 21
were excluded and 53 selected for inclusion (Fig. 1).
These papers comprised 48 superiority trials, in which
an intensive treatment strategy was compared with a less
intensive strategy, and 6 head-to-head trials comparing
combination DMARDs with biologic treatments. The
BeST paper is included in both of these groups.
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Characteristics of included studies
Twenty two superiority trials evaluated patients reported
as having early RA. Their maximum disease durations
ranged from 3 months to 3 years. Mean or median disease
durations, reported in 20 of these trials, ranged from 1 to
11 months (mean 6 months). Four of these trials studied
patients with very early disease, less than 6 months from
diagnosis. One trial had two different intensive treatment
arms (combination DMARDs and biologics) which were
both included. Six trials had two or three intensive treat-
ment arms: in three trials biologic monotherapy treatment
arms were omitted; in another three trials only licensed
combination regimens were included.
Twenty six superiority trials evaluated patients with
established RA. Six of these trials specified maximum
disease durations (from 5 to 20 years). Mean or median
disease durations, reported in all of these trials, ranged
from 1 to 12 years (mean 8 years). One trial had two con-
trol groups (methotrexate or sulfasalazine monotherapy)
and these were combined. Sixteen trials had two or more
intensive treatment arms: three had two different licensed
intensive treatments (biologics and JAK inhibitors) which
were both included; in one trial the biologic monotherapy
treatment arm was omitted; in a further 12 trials only
licensed combination regimens were included.
Overall 19,752 RA patients were studied: 7300 in early
RA and 12,452 with established RA (Table 1). There were
46 conventional RCTs, one was open label and one
quasi-experimental. Twenty four trials had 2-arms, 17 had
3-arms and 7 had over three arms. The trials often reported
Fig. 1 PRISMA Diagram Outlining Search Strategy
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outcomes at several different time-points, but their primary
outcomes were reported at 6 months in 21 trials, at
12 months in 19 trials and at longer intervals in 8 trials (2
at 18 months, 5 at 24 months and 1 at 36 months).
DAS28 remissions (DAS28 < 2.6) were reported in 38/
48 superiority trials and 4/6 head-to-head trials. DAS re-
missions (DAS < 1.6) were reported in 5/48 superiority
trials and 2/6 head-to-head trials. Five superiority trials
reported other remissions (using SDAI in 3 and unique
study-specific criteria in 2). In addition, 12 superiority
trials reported some or all of the new EULAR/ACR
remission criteria.
Treat-to-target strategies were included within 8/48
superiority trials and 3/6 head-to-head trials, though
there were substantial differences in how these strategies
were delivered.
Remission in superiority trials
Overall in the 48 trials 3013/11,259 patients achieved
remission with intensive treatment compared with 1211/
8493 patients receiving non-intensive therapy (Table 2).
Analysis of the 53 comparisons in these trials using the ran-
dom effects relative risk model showed there was a highly
significant benefit for intensive treatment (RR 2.23; 95% CI
1.90, 2.61). There was marked heterogeneity between
studies; I2 was 84%.
In the 38 trials (40 comparisons) reporting DAS28 remis-
sions the random risk ratio was 2.26 (95% CI 1.89, 2.71); in
the 10 trials (12 comparisons) reporting other remission
criteria the random risk ratio was 2.13 (95% CI 1.53, 2.98).
The random risk ratios showed significant effects with trials
of 6 months, 12 months and longer durations. Although
the random ratio was somewhat higher in trials of 6 months
duration, 17/21 trials (20/24 comparisons) were in estab-
lished RA and in these the random risk ratio was 4.82 (95%
CI 2.85, 8.13); in the 4 trials (4 comparisons) lasting
6 months in early RA the random risk ratio was 1.94 (95%
CI 1.21, 3.11). In the 8 trials (9 comparisons) involving
TTT strategies as part of intensive treatment the random
risk ratio was 1.62 (95% CI 1.30, 2.03).
In the 22 trials in early RA with intensive treatments
trials with 1756/3993 patients achieved remission with
intensive treatment compared with 903/3307 patients re-
ceiving monotherapy. One trial evaluated two intensive
treatment regimens and there were consequently 23
comparisons; 13 evaluated TNF inhibitors, 5 evaluated
other biologics and 5 evaluated combination DMARDs.
Analysis of the 23 comparisons in these trials showed a
significant overall benefit for intensive treatment (RR
Table 2 Effectiveness In Superiority Trials Assessed By Random Risk Ratio and Heterogeneity
Treatments Trials Comparisons Random Risk Ratio (95% CI) Heterogeneity
All All 48 52 2.23 (1.90, 2.61) I2 = 84%
DAS28 Remissions 38 40 2.26 (1.89, 2.71) I2 = 85%
Other Remission Criteria 10 12 2.13 (1.53, 2.98) I2 = 81%
6 Month Duration 21 24 3.78 (2.60, 5.51) I2 = 86%
12 Month Duration 19 20 1.73 (1.44, 2.09) I2 = 82%
18–36 Month Duration 8 8 1.84 (1.39, 2.42) I2 = 79%
Used TTT Strategy 8 9 1.62 (1.30, 2.03) I2 = 75%
Early Alla 22 23 1.56 (1.38, 1.76) I2 = 74%
TNF Inhibitors 13 13 1.44 (1.26, 1.66) I2 = 62%
Other Biologics 5 5 2.00 (1.53, 2.63) I2 = 79%
Combination DMARDSb 5 5 1.46 (1.11, 1.93) I2 = 73%
Used TTT Strategy 6 7 1.51 (1.22, 1.88) I2 = 72%
Established All 26 29 4.21 (2.92, 6.07) I2 = 86%
TNF Inhibitors 10 10 3.59 (2.14, 6.03) I2 = 70%
Other Biologics 10 10 6.81 (2.62, 17.7) I2 = 95%
Combination DMARDS 3 3 2.41 (1.14, 5.10) I2 = 67%
JAK Inhibitors 6 6 3.39 (2.14, 5.36) I2 = 0%
Used TTT Strategy 2 2 2.39 (0.90, 6.32) I2 = 83%
aThe 4 very early trials which enrolled patients with disease durations no more than 6 months involved 4 comparisons with a random risk ratio (95% CI) of 1.47
(1.03, 2.10) and I2 72%
bExcluding the Schipper et al. study in which some patients in both groups had DMARD monotherapy, DMARD combination therapy and TNF inhibitors leaves 4
trials with 4 comparisons with a random risk ratio (95% CI) of 1.38 (1.01, 1.88) and I2 71%
Abbreviations: DAS28 Disease Activity Score for 28 joints, TNF Tumour necrosis factor, DMARDs Disease modifying anti-rheumatic drugs, JAK Janus kinase, TTT Treat
To Target
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1.56; 95% CI 1.38, 1.76). There was marked heterogen-
eity in these studies; I2 was 74% (Table 2). A funnel plot
showed a symmetrical pattern in these trials (result not
shown). Four trials enrolled patients with disease dura-
tions no more than 6 months and these showed a similar
benefit for intensive treatment (RR 1.47; 95%CI 1.03,
2.10) Comparison of the different intensive treatment
regimens in early RA patients showed similar impacts of
different intensive treatments; these ranged from a ran-
dom risk ratio of 1.43 with TNF inhibitors to 2.00 with
other biologics. TTT strategies also increased remissions
with a random risk ratio of 1.51.
In the 26 established RA trials 1257/7266 patients
achieved remission with intensive treatment compared with
308/5186 patients receiving monotherapy. Three trials eval-
uated two intensive treatment regimens and consequently
there were 29 comparisons: 10 evaluated TNF inhibitors,
10 evaluated other biologics, 3 evaluated combination
DMARDs and 6 evaluated JAK inhibitors. Analysis of these
29 comparisons trials showed a significant overall benefit
for intensive treatment (RR 4.21; 95% CI 2.92, 6.07). There
was marked heterogeneity in these studies; I2 was 86%
(Table 2). A funnel plot showed an asymmetrical pattern in
these trials (result not shown). Comparison of the different
intensive treatment regimens in established RA patients
showed some differences in the magnitude of effects; ran-
dom risk ratios ranged from 2.41 with combination
DMARDs to 6.81 with other biologics (tocilizumab,
adalimumab and rituximab); however, as the confidence
intervals overlapped there was no evidence these differ-
ences were significant. Only two trials used TTT strategies
and although these increase remissions the 95% confidence
intervals showed the finding may not have been significant
(random risk ratio 2.39; 95% CI 0.90, 6.32).
Using a fixed effects model gave similar findings. In all
trials the risk ratio was 2.06 (95%CI 1.94, 2.18), in early
RA trials it was 1.64 (95% CI 1.54, 1.74) and in estab-
lished RA the risk ratio was 3.32 (95% CI 2.94, 3.74).
Interestingly the fixed model indicated TTT strategies in
established RA in two trials may have been significant
(risk ratio 2.19, 95% CI 1.50, 3.19.
Remission in head to head trials
Overall in the 6 trials 317/787 patients achieved
remission with TNF inhibitors compared with 229/671
of patients receiving combination DMARD therapies.
Analysis of these 6 trials using the random effects rela-
tive risk model (Table 3) showed there was a no different
between treatment strategies (RR 1.06; 95% CI 0.93.
1.21). There was little heterogeneity between studies; I2
was 21%. Comparing 4 early RA and 2 established RA
trials separately also showed no evidence of a significant
difference between groups (Table 3). However, compari-
sons of the first 6 months results in the two established
RA trials showed more remissions with TNF inhibitors
using the random effects relative risk model (RR 1.74,
95% CI 1.14, 2.64). The fixed effects model gave similar
findings (RR 1.90; 95% CI 1.17, 3.10).
Frequency of remissions
There were marked differences in the frequency of
remissions in active and control groups in both early
and established RA (Fig. 2). In early RA the average fre-
quency of remissions with active treatment was 49%: in
10 early RA trials 50% or more active patients achieved
remissions; the highest rate was 86% in the U-Act-Early
(tocilizumab) trial and the lowest rate was 18% in the St
Clair (Infliximab) trial. In early RA controls the average
frequency of remission was 34%: in four trials 50% or
more controls achieved remissions; and the lowest rate
in controls was 18% in the Image (rituximab) trial. The
average difference in remission rates between active and
control group in early RA trials was 15%.
In established RA the average frequency of remissions
with active treatment was 19%: in only one trial did 50%
or more active patients achieved remission (65% in the
Ticora trial of combination DMARDs); in 14 trials 10%
or less active patients achieved remission and, in the Re-
flex, (rituximab) and RA Beam (baricitinib and adalimu-
mab) trials only 3% of patients achieved remissions. In
established RA controls the average frequency of remis-
sion was 6%: in 22 trials less than 5% of controls
achieved remissions; and in the Reflex (rituximab) trial
no control patient achieved an end-point remission. The
average difference in remission rates between active and
control group in early RA trials was 13%.
Quality and risk of Bias
Quality assessment, using the Cochrane Collaboration
tool for assessing risk of bias, showed overall quality was
high with low risks of bias (Table 1).
Discussion
TNF Inhibitors, other biologics and combination
DMARDS were all effective in increasing remission in
early and established RA. Treat to target strategies,
which usually involved intensive DMARDs, were also
Table 3 Effectiveness In Head To Head Trials Comparing
Biologic with Combination DMARD Strategies Assessed By
Random Risk Ratio and Heterogeneity
Trials Random Risk
Ratio (95% CI)
Heterogeneity
All 6 1.06 (0.93, 1.21) I2 = 21%
Early 4 1.05 (0.88, 1.24) I2 = 40%
Established 2 1.21 (0.88, 1.68) I2 = 0%
Established First 6 Months 2 1.74 (1.14, 2.64) I2 = 0%
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effective. JAK inhibitors were similarly effective in estab-
lished RA; there was no data about their impact in early
disease. Although other biologics achieved numerically
higher risk ratios in both early and established RA the
overlapping confidence intervals gave no support to the
view that these differences are clinically significant. The
benefits of different types of intensive treatment were
therefore broadly similar. Trials of varying durations,
from 6 months to more than 12 months, all showed in-
tensive treatments increased remissions. There was no
evidence that patients with very early RA of no more
than 6 months disease duration benefited more from
intensive treatments. We excluded trials with
durations of less than 6 months to ensure we did not
disadvantage the assessment of intensive treatment
strategies using slower acting DMARDs. The
head-to-head trials supported the similarities between
treatments with combination DMARD strategies and
TNF inhibitor strategies, which achieved similar
end-point remission rates. There was however, some
evidence that TNF inhibitors increased the early re-
mission rates, in keeping with their relatively rapid
Fig. 2 Remissions in control and active groups shown as percent patients in each group in early and established RA
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onset of action compared to conventional DMARD
combinations.
TNF Inhibitors, other biologics and combination
DMARDS were all effective in increasing remission in
early and established RA. There was no evidence that
patients with very early RA of no more than 6 months dis-
ease duration benefited more from intensive treatments.
JAK inhibitors were similarly effective in established RA;
there was no data about their impact in early disease.
Although other biologics achieved numerically higher risk
ratios in both early and established RA the overlapping
confidence intervals gave no support to the view that
these differences are clinically significant. The head-to-
head trials supported the similarities between treatments
with combination DMARD strategies and TNF inhibitor
strategies, which achieved similar end-point remission
rates. There was however, some evidence that TNF inhibi-
tors increased the early remission rates, in keeping with
their relatively rapid onset of action compared to conven-
tional DMARD combinations.
The overall quality of the studies was relatively high.
However, there was evidence of marked heterogeneity in
their findings with most comparisons having high I2
values. This heterogeneity meant that in some intensive
treatment arms in early RA over 70% patients achieved
remission while in other intensive treatment arms in
established RA under 10% patients achieved remission.
These differences are likely to reflect patient selection
more than treatment efficacy, with very early RA
patients having no previous DMARDs are highly likely
to achieve remission with intensive treatment while
established RA patients who have failed multiple prior
treatments are unlikely to do so.
The most likely explanation for the asymmetrical fun-
nel plot in trials in established RA relates to specifically
including studies using treatments in their licensed indi-
cation which were published between 2000 and 2017. A
consequence is that potential intensive treatments which
were evaluated in RA patients but were not found to be
effective, were not included. Firstly, small initial studies
with new drugs which would have shown negative re-
sults for remissions were not included as the treatments
were never licensed for RA. An example is the spleen
tyrosine kinase inhibitors [81]. Secondly, some TNF
inhibitors were not effective in RA and were therefore
not licensed; an example is Lenercept, which failed to
show sustained benefit in clinical trials [82]. Finally,
combinations with DMARDs were tried in the 1980’s,
before remission was measured or reported; these trials
were mainly negative [83]; subsequent trials of intensive
DMARD combinations reporting remission which were
published after 2000 studied treatments which were
known to be effective in combination. These factors
mean the funnel plot of remissions in established RA
would not include small trials with negative findings
because of the selection criteria used. As this report fo-
cuses on the benefits of different intensive treatment
strategies using licensed treatments given at their
approved dosages we do not think an asymmetric funnel
plot changes our conclusions.
Our systematic review has a number of limitations.
Firstly, studies not reporting remission data were
excluded, though they often show clinically important
improvements with intensive treatment. Secondly, studies
reported remissions differently; for example, DAS and
DAS28 remissions are similar but not identical. Thirdly,
studies were of variable duration and comparing remission
rates over 6 and 12 months or more is not ideal; however,
variations in treatments and patient selection meant there
was no evidence for one particular time point being best.
Fourthly, studies differed in the way they handled
non-responders, with some trials stopping treatment if
patients had not responded within 3 months or so and
applying non-responder imputations. This approach may
alter the remission rates in the non-intensive treatment by
making it appear smaller than it might have been if treat-
ment was continued. Fifthly, as mentioned previously,
studies enrolled different patient groups in whom the like-
lihood of achieving remissions was very different. Sixthly,
the intensive combination DMARD regimens used in the
trials have been combined together, even though they rep-
resent a wide range of different strategies, not all of which
appeared highly effective. In one study by Schipper et al.
[58] some patients in active and control groups had
monotherapy and others had biologics, so the trial is not
just a comparison of one treatment strategy; however, ex-
cluding it made no difference to the conclusions. Finally,
there is debate about the benefits of combining the results
of different trials in a meta-analysis, considering their
potential degrees of clinical heterogeneity. As we have also
undertaken extensive sub-group analyses we consider the
approach we have taken is justified in this particular
clinical context.
Our results have several implications for clinical prac-
tice. Firstly, they show that intensive treatment strategies
lead to more remissions than conventional care in both
early and established RA. This finding is generally
supportive of the treat-to-target approach currently
recommended [7, 8], although we have not attempted to
dissociate the impact of giving intensive treatment from
the impact of the target. Secondly, they show that initial
treatment with conventional DMARD combinations has
similar effectiveness to early biologics. This finding is
supportive of the current recommendations about bio-
logic treatments from the National Institute for Health
and Care Excellence (NICE), which recommend trying
combination DMARDs before biologic treatment [84].
Thirdly, they question whether remission is necessarily
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the ideal target for treatment in established RA, as it is
only achieved by a minority of patients in most trials of
intensive treatment. There may be greater value of aim-
ing for low disease activity states, in which case these
need to be measured in future trials. The EULAR good
response criteria can be used to assess the frequency of
achieving low disease activity states measures using
DAS28. Current guidance on treat to target includes
aiming for low disease activity in some patients.
One issue this review cannot address is treatment
sequencing. Some experts believe most early RA patients
should receive methotrexate monotherapy initially for a
few months and only have intensive treatments if they
fail to respond. Other experts recommend early inten-
sive treatment followed by treatment tapering. It is
possible to find individual trials within our systematic
review, which support both options, but there is no sys-
tematic evidence to support or refute either approach.
One final pair of inter-related uncertainties is the opti-
mal time to assess remission and the most suitable as-
sessment to evaluate its presence. Combining superiority
and head-to-head trials (Tables 1 and 4) shows 23 (43%)
lasted 12 months, 20 (38%) lasted 6 months and 10
(19%) lasted over 12 months, with the longest (BROSG
trial evaluating combination DMARDs) lasting 3 years.
This finding suggests trials of 12 months or longer seem
preferable. Although most trials reported DAS28
remissions, this represents an historical target and there
is now greater emphasis on stricter remission criteria.
Conclusions
Intensive treatment with combination DMARDs, biologics
or JAK inhibitors increases the frequency of remission
compared to control non-intensive strategies. The benefits
are seen in both early and established RA. The relative
merits of different remission criteria in trials is a complex
question but changing criteria has the disadvantage of
making it difficult to compare trials with newer criteria
and those using more historic methods.
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